DNLIDenali Therapeutics Inc.

$3B

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M-79.3% YoY

Gross Profit

$27M100.0% margin

Operating Income

-$213M-799.1% margin

Net Income

-$198M-740.7% margin

EPS (Diluted)

$-2.07

Cash Flow

Operating Cash Flow

-$152M

Free Cash Flow

-$169M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$553M

Total Liabilities

$158M

Stockholders' Equity

$395M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$129M	-79.3%
Gross Profit	$27M	$129M	-79.3%
Operating Income	-$213M	-$46M	-359.7%
Net Income	-$198M	-$36M	-445.3%

DNLI FY 2019 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena